FCGR2A/CD32A and FCGR3A/CD16A variants and EULAR response to tumor necrosis factor-α blockers in psoriatic arthritis: A longitudinal study with 6 months of followup

Journal of Rheumatology

Volumn 39, Issue 5, 2012, Pages 1035-1041

  Ramírez, Julio ^a   Fernández Sueiro, José Luis ^b   López Mejías, Raquel ^a   Montilla, Carlos ^a   Arias, Maite ^a   Moll, Concepción ^a   Alsina, Mercé ^a   Sanmarti, Raimon ^a,d   Lozano, Francisco ^a,c,d   Cañete, Juan D ^a,d  

^a HOSPITAL CLÍNIC   (Spain)

^b HOSPITAL JUAN CANALEJO   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

^d INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

EULAR response; Gene polymorphism; Psoriatic arthritis; Tumor necrosis factor blockers

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; CD16A ANTIGEN; ETANERCEPT; FC RECEPTOR IIA; GENOMIC DNA; GOLIMUMAB; INFLIXIMAB; LYMPHOCYTE ANTIGEN; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DRUG EFFICACY; FCGR2A GENE; FCGR3A GENE; FEMALE; FOLLOW UP; GENE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; FEMALE; FOLLOW-UP STUDIES; GENETIC VARIATION; HUMANS; IMMUNOGLOBULIN G; LONGITUDINAL STUDIES; MALE; METHOTREXATE; MIDDLE AGED; RECEPTORS, IGG; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84860740106     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.110980     Document Type: Article

References (24)

1. Licastro F, Chiapelli M, Ianni M, Porcellini E. Tumor necrosis factor-alpha antagonists: Differential clinical effects by different biotechnological molecules. Int J Immunopathol Pharmacol 2009;22:567-72.
2. Van Sorge NM, Van der Pol W-L, Van de Winkel J G J. FCGR polymorphisms: Implications for function, disease susceptibility and immunotherapy. Tissue Antigens 2003;61:189-202. (Pubitemid 36605541)
3. Warmerdam PA, Van de Winkel JG, Vlug A, Westerdaal NA, Capel PJ. A single amino acid in the second Ig-like domain of the human FC gamma receptor II is critical for human IgG2 binding. J Immunol 1991;147:1338-43.
4. Parren PW, Warmedam PA, Boeije LC, Arts J, Westerdaal NA, Vlug A, et al. On the interaction on IgG subclasses with the low affinity FC gamma RIIa (CD 32) on human monocytes, neutrophils and platelets. Analysis of a functional polymorphism to human IgG2. J Clin Invest 1992;90:1537-46.
5. Koene HR, Kleijer M, Algra J, Roos D, von dem Borne AE, de Haas M. FCGRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell FCGRIIIa, independently of the FCGRIIIa-48L/R/H phenotype. Blood 1997;90:1109-14. (Pubitemid 27314146)
6. Hatjiharissi E, Xu L, Santos DD, Hunter ZR, Ciccarelli BT, Verselis S, et al. Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the FCGRIIIa-158 V/V and V/F polymorphism. Blood 2007;110:2561-4. (Pubitemid 47523179)
7. Anandarajah AP, Ritchlin CT. The diagnosis and treatment of early psoriatic arthritis. Nat Rev Rheumatol 2009;5:634-41.
8. Brandt J, Braun J. Anti-TNF-alpha agents in the treatment of psoriatic arthritis. Expert Opin Biol Ther 2006;6:99-107. (Pubitemid 43259891)
9. Cañete JD, Suárez B, Hernández MV, Sanmartí R, Rego I, Celis R, et al. Influence of variants of FCG receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor alpha therapy in rheumatoid arthritis. Ann Rheum Dis 2009;68:1547-52.
10. Tutuncu Z, Kavanaugh A, Zvaifler N, Corr M, Deutsch R, Boyle D. FCG receptor type IIIA polymorphisms influence treatment outcomes in patients with inflammatory arthritis treated with tumor necrosis factor alpha-blocking agents. Arthritis Rheum 2005;52:2693-6. (Pubitemid 41369097)
11. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H; CASPAR Study Group. Classification criteria for psoriatic arthritis: Development of new criteria from a large international study. Arthritis Rheum 2006;54:2665-73. (Pubitemid 44205029)
12. Fernández Sueiro JL, Juanola X, Cañete JD, Torre Alonso JC, García-Vicuña R, Queiró Silva R, et al. Consensus statement of the Spanish Society of Rheumatology on the management of biologic therapies in psoriatic arthritis. Reumatol Clin 2011;7:172-8.
13. Fransen J, van Riel PL. The Disease Activity Score and the EULAR response criteria. Clin Exp Rheumatol 2005;23:S93-99. (Pubitemid 46657516)
14. Leppers-van de Straat FG, van der Pol WL, Jansen MD, Sugita N, Yoshie H, Kobayashi T, et al. A novel PCR-based method for direct Fc gamma receptor IIIa (CD16) allotyping. J Immunol Methods 2000;242:127-32.
15. Marnell L, Mold C, Du Clos TW. C-reactive protein: Ligands, receptors and role in inflammation. Clin Immunol 2005;117:104-11. (Pubitemid 41407719)
16. Saber TP, Ng CT, Renard G, Lynch BM, Pontifex E, Walsh CA, et al. Remission in psoriatic arthritis: Is it possible and how can it be predicted? Arthritis Res Ther 2010;12:R94.
17. Morales-Lara MJ, Conesa-Zamora P, García-Simón MS, Pedrero F, Santaclara V, Perez-Guillermo M, et al. Association between the FCGR3A V158F polymorphism and the clinical response to infliximab in rheumatoid arthritis and spondyloarthritis patients. Scand J Rheumatol 2010;39:518-20.
18. Vandooren B, Noordenbos T, Ambarus C, Krausz S, Cantaert T, Yeremenko N, et al. Absence of a classically activated macrophage cytokine signature in peripheral spondylarthritis, including psoriatic arthritis. Arthritis Rheum 2009;60:966-75.
19. Ho P, Bruce IN, Silman A, Symmons D, Newman B, Young H, et al. Evidence for common genetic control in pathways of inflammation for Crohn's disease and psoriatic arthritis. Arthritis Rheum 2005;52:3596-602. (Pubitemid 41612229)
20. Louis EJ, Watier HE, Schreiber S, Hampe J, Taillard F, Olson A, et al. Polymorphism in IgG Fc receptor gene FCGR3A and response to infliximab in Crohn's disease: A subanalysis of the ACCENT I study. Pharmacogenet Genomics 2006;16:911-4. (Pubitemid 44772809)
21. Kastbom A, Bratt J, Ernestam S, Lampa J, Padyukov L, Söderkvist P, et al. FCG receptor type IIIA genotype and response to tumor necrosis factor alpha-blocking agents in patients with rheumatoid arthritis. Arthritis Rheum 2007;56:448-52.
22. Treon SP. Fcg receptor predictive genomic testing and the treatment of indolent non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk 2010;10:321-2.
23. Zhuang Y, Xu W, Shen Y, Li J. Fcg receptor polymorphisms and clinical efficacy of rituximab in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Clin Lymphoma Myeloma Leuk 2010;10:347-52.
24. Dornan D, Spleiss O, Yeh R-F, Duchateau-Nguyen G, Dufour A, Zhi J, et al. Effect of FCGR2A and FCGR3A variants on CLL outcome. Blood 2010;116:4212-22.